

Resource Summary Report

Generated by [RRID](#) on Aug 26, 2026

pCVL Traffic Light Reporter 1.1 (Sce target) Ef1a Puro

RRID:Addgene_31482

Type: Plasmid

Proper Citation

RRID:Addgene_31482

Plasmid Information

URL: <http://www.addgene.org/31482>

Proper Citation: RRID:Addgene_31482

Insert Name: Traffic Light Reporter 1.1 (Sce Target) EF Puro

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:21743461](#)

Vector Backbone Description: Backbone Size:5000; Vector Backbone:pCVL; Vector Types:Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: pCVL Traffic Light Reporter 1.1 (Sce target) Ef1a Puro

Relevant Mutation: mCherry has M9S and M16L mutations. This is what the ".1" means.

Record Creation Time: 20220422T222136+0000

Record Last Update: 20260815T081335+0000

Ratings and Alerts

No rating or validation information has been found for pCVL Traffic Light Reporter 1.1 (Sce target) Ef1a Puro.

No alerts have been found for pCVL Traffic Light Reporter 1.1 (Sce target) Ef1a Puro.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li P, et al. (2025) OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer. Nature communications, 16(1), 7209.

Palek M, et al. (2024) RAD18 directs DNA double-strand break repair by homologous recombination to post-replicative chromatin. Nucleic acids research, 52(13), 7687.

Gregorczyk M, et al. (2023) Functional characterization of C21ORF2 association with the NEK1 kinase mutated in human in diseases. Life science alliance, 6(7).

Morales-Valencia J, et al. (2023) Chromatin-Associated SIN3B Protects Cancer Cells from Genotoxic Stress-Induced Apoptosis and Dictates DNA Damage Repair Pathway Choice. Molecular cancer research : MCR, 21(9), 947.

Liu Y, et al. (2022) Targeting telomerase reverse transcriptase with the covalent inhibitor NU-1 confers immunogenic radiation sensitization. Cell chemical biology, 29(10), 1517.

Mukherjee J, et al. (2021) RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells. Science translational medicine, 13(592).

Mehibel M, et al. (2021) Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. The Journal of clinical investigation, 131(11).

Banerjee D, et al. (2021) A non-canonical, interferon-independent signaling activity of cGAMP triggers DNA damage response signaling. Nature communications, 12(1), 6207.

Shinoda K, et al. (2021) The dystonia gene THAP1 controls DNA double-strand break repair choice. Molecular cell, 81(12), 2611.

Brnich SE, et al. (2021) A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation. The Journal of molecular diagnostics : JMD, 23(7), 847.

Ghanta KS, et al. (2021) 5'-Modifications improve potency and efficacy of DNA donors for precision genome editing. eLife, 10.

Palaniappan TK, et al. (2020) CAM-Delam: an in vivo approach to visualize and quantify the delamination and invasion capacity of human cancer cells. Scientific reports, 10(1), 10472.

Ohba S, et al. (2020) Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity. Cell reports, 31(2), 107518.

Burdova K, et al. (2019) WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors. Cells, 8(10).

Mukherjee C, et al. (2019) RIF1 promotes replication fork protection and efficient restart to maintain genome stability. *Nature communications*, 10(1), 3287.

Hustedt N, et al. (2019) Control of homologous recombination by the HROB-MCM8-MCM9 pathway. *Genes & development*, 33(19-20), 1397.

Zhao C, et al. (2018) HIT-Cas9: A CRISPR/Cas9 Genome-Editing Device under Tight and Effective Drug Control. *Molecular therapy. Nucleic acids*, 13, 208.

Zhao C, et al. (2018) Multiple Chemical Inducible Tal Effectors for Genome Editing and Transcription Activation. *ACS chemical biology*, 13(3), 609.

Lu J, et al. (2018) Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. *Nucleic acids research*, 46(5), e25.

Noordermeer SM, et al. (2018) The shieldin complex mediates 53BP1-dependent DNA repair. *Nature*, 560(7716), 117.